November 25, 2022
Your weekly roundup of the latest news from Drug Topics®.
Take a look back at our most popular health system coverage for 2022.
November 24, 2022
Take a look back at our most popular COVID-19 coverage for 2022.
November 23, 2022
The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Take a look back at our most popular diabetes coverage for 2022.
November 22, 2022
CPESN payers and their success stories.
November 18, 2022
CSL Behring's gene therapy, called EntranaDez, may be approved later this month. BioMarin, Pfizer, Bayer and Freeline Therapeutics also have gene therapies for hemophilia in development.
November 17, 2022
Health disparities in care were made worse by the pandemic.
FDA keeps its user fees but fails to gain important reforms.
